A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
Completed
UCB Pharma
Phase 2
2004-10-11
Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic
neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor
down-titration.
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
Completed
UCB Pharma
Phase 2
2005-11-07
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50
mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Completed
UCB Biopharma S.P.R.L.
Phase 2
2017-02-06
The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV)
compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy
Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Recruiting
UCB Biopharma S.P.R.L.
Phase 3
2017-08-22
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to
placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial
seizures with or without secondary generalization despite current treatment with 1 or 2
concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in
subjects >= 16 years to 80 years of age.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
